IVF: gonadotrophins similar in amount required to achieve live birth

  • Bordewijk EM & al.
  • Hum Reprod Open
  • 1 Jan 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Differences are small in the required amounts of recombinant follicle-stimulating hormone (rFSH), highly purified FSH (HP-FSH), or highly purified human menopausal gonadotrophin (HP-hMG) to reach live birth after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), according to a systematic review and meta-analysis.

Why this matters

  • This study suggests that treatment choice should be based on convenience, availability, cost, and patient preference.

Key results

  • There was no evidence of a difference in the amount of rFSH vs HP-hMG (mean difference, −37 IU; 95% CI, −115 to 41 IU) or rFSH vs HP-FSH (mean difference, −31 IU; 95% CI, −290 to 228 IU) required to achieve live birth.
  • rFSH vs HP-hMG was associated with lower rates of clinical pregnancy (rate ratio [RR], 0.90; 95% CI, 0.81-1.00) and live birth (RR, 0.88; 95% CI, 0.78-0.99) compared with HP-hMG.
  • rFSH and HP-FSH were associated with similar rates of clinical pregnancy (RR, 1.03; 95% CI, 0.94-1.13) and live birth (RR, 1.03; 95% CI, 0.90-1.18).

Study design

  • 28 studies including 7553 women undergoing ovarian stimulation with rFSH, HP-hMG, or HP-FSH were subjected to meta-analysis.
  • Funding: None disclosed.

Limitations

  • Heterogeneity between included studies.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit